Low‐dose psilocybin in short‐lasting unilateral neuralgiform headache attacks: results from an open‐label phase Ib ascending dose study
The study met with recruitment difficulties and cognition could not be assessed during the acute experience due to subjective dose intensity, likely mediated in part by expectancy effects. The clinical results provide no conclusive evidence for the use of psilocybin in SUNHA. We suggest that accounting for psychological factors in chronic SUNHA may be an important facet of treatment.
Authors
- Fiona Dunbar
- Manjit Singh Matharu (ORCID: https://orcid.org/0000-0002-4960-2294)
- Giorgio Lambru (ORCID: https://orcid.org/0000-0002-2780-4776)
- Catherine Bird (ORCID: https://orcid.org/0000-0002-8656-6931)
- Matthew Butler (ORCID: https://orcid.org/0000-0002-9734-6539)
- James Rucker (ORCID: https://orcid.org/0000-0003-4647-8088)
- Carolina Maggio (ORCID: https://orcid.org/0000-0001-5550-5557)
- Mathieu Seynaeve
- Kete Campbell‐Coker
- Sadie Hambleton
- Sanjay Cheema
Institutions
- St Thomas' Hospital (GB)
- Beckley Foundation (GB)
- King's College London (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1111/head.14837
- Citations
- 9
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.75
Funders
- Wellcome Trust
- National Institute for Health and Care Research